Pyrimidine metabolism was studied in the obligate intracellular bacterium Chlamydia psittaci AA Mp in the wild type and a variety of mutant host cell lines with well-defined mutations affecting pyrimidine metabolism.C. psittaci AA Mp cannot synthesize pyrimidines de novo, as assessed by its inability to incorporate aspartic acid into nucleic acid pyrimidines. In addition, the parasite cannot take UTP, CTP, or dCTP from the host cell, nor can it salvage exogenously supplied uridine, cytidine, or deoxycytidine. The (7,20). The species C. trachomatis and C pneumoniae are primarily human pathogens (6, 26).In contrast, C. psittaci has been isolated from humans and a very large number of avian and mammalian species, in which it produces a variety of diseases (26,28). Despite the clinical and economic importance of chlamydiae, many aspects of their basic biology have not been studied and the metabolic relationships that exist between the parasites and their hosts remain largely unknown (20). This is, in part, due to the fact that axenic growth of chlamydiae has not been realized. In addition, host-free chlamydiae display limited metabolic activity (12,20).Our laboratory is particularly interested in nucleotide metabolism in chlamydiae. To study nucleotide metabolism in C. trachomatis, we have employed an in situ approach with well-defined mutant host cell lines and several different radiolabelled nucleic acid precursors (4,5,18,24,29,30). The results generated indicate that C. trachomatis (i) cannot de novo synthesize purines or pyrimidines, (ii) lacks the ability to salvage preformed purine or pyrimidine nucleobases and (deoxy)nucleosides, (iii) can obtain all four ribonucleotides directly from the host cell, (iv) encodes a ribonucleotide reductase and thymidylate synthase for synthesizing deoxyribonucleotides from host-derived ribonucle-* Corresponding author. t Present address: